ASSETS UNDER MANAGEMENT
Venture Capital Funds
In 2003, BioCrossroads established the Indiana Future Fund I as a leading source of venture financing for Indiana opportunities. The Indiana Future Fund I is a $73 million fund of funds that is managed by AlpInvest Partners. Significant investments include Endocyte (Nasdaq:ECYT), Purdue’s first start-up to reach $1.5B market cap and Colucid, purchased by Eli Lilly and Company for $960M in 2018. In December 2009, BioCrossroads established a successor fund – the $58 million INext Fund. As with the Indiana Future Fund, the INext Fund is organized as a return-driven, fund of funds that is also managed by AlpInvest Parners. In 2017, the State of Indiana established the Next Level Indiana Fund, a $250 million return-driven fund of funds managed by 50 South Capital and focused on Indiana’s innovation community. Members of BioCrossroads executive team serve on an advisory board to 50 South Capital.